Clinical trial
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease…
NCT00369226 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00369226 |
|---|---|
| Title | Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation |
| Official title | Phase I/II Trial of Bortezomib (Velcade) in Addition to Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Peripheral Blood Stem Cell Transplantation |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hematologic Malignancies |
| Intervention type | Drug, Procedure |
| Interventions | Bortezomib (Velcade), Tacrolimus, Methotrexate, blood stem cell transplantation |
| Enrollment | 45 |
| Start date | Aug 1, 2006 |
| Primary completion | Jul 1, 2010 |
| Completion | Sep 1, 2011 |
| First posted | Aug 29, 2006 |
| Last update posted | Jul 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: